

Radiotherapies and radioimmunotherapies will require prior authorization

Effective March 1, 2021, Amerigroup will require prior authorization (PA) for the additional injectable drugs listed below. Please refer to the Precertification Look Up Tool at <https://providers.amerigroup.com/TX> or the Availity* Portal for authorization requirements. Noncompliance with the new requirements may result in denied claims.

PA requirements will be added to the following codes:

- A9543 Injection, Yttrium Y-90 ibritumomab tiuxetan (Zevalin)
- A9590 Injection, Iodine I-131, iobenguane, 1 mCi (Azedra)
- A9513 Injection, Lutetium Lu 177, dotatate, therapeutic, 1 millicurie (Lutathera)
- A9606 Injection, Radium ra-223 dichloride, therapeutic, per microcurie (Xofigo)

Please use one of the following methods to request PA:

- Web: <https://www.availity.com>
- Phone: **1-800-454-3730**
- Fax: **1-844-512-8995**

Federal and state law, as well as state contract language, including definitions and specific contract provisions/exclusions, take precedence over these PA rules and must be considered first when determining coverage.

* Availity, LLC is an independent company providing administrative support services on behalf of Amerigroup.

<https://providers.amerigroup.com>